Open AccessSURGICAL MANAGEMENT OF PATIENTS DIAGNOSED WITH MALIGNANT PHYLLODES TUMOR OF THE BREAST IN THE NATIONAL ONCOLOGY INSTITUTE “DR. JUAN TANCA MARENGO” SOLCA – GUAYAQUIL
Author(s) -
Freddy Rueda Safady,
Fernando Miñán Arana,
Francisco Xavier Hernández Manrique,
Pablo Ulloa Ochoa
Publication year - 2022
Publication title -
international journal of research - granthaalayah
Language(s) - English
Resource type - Journals
eISSN - 2394-3629
pISSN - 2350-0530
DOI - 10.29121/granthaalayah.v10.i4.2022.4494
Subject(s) - medicine , lumpectomy , phyllodes tumor , incidence (geometry) , breast cancer , mastectomy , modified radical mastectomy , oncology , general surgery , cancer , physics , optics
The aim is to establish the real relationship of incidence of the Malignant phyllodes Tumor of Breast and its effective surgical approach in patients treated at the Oncological Institute of Guayaquil, the reference center of Ecuador.
Objective: To establish the surgical management of Malignant phyllodes Tumors of Breast in the Oncological Institute of Ecuador SOLCA.
Method: An analysis of the cases diagnosed and operated in the Oncological Institute of Guayaquil SOLCA in the period September 2009 to September 2019, based on a retrospective descriptive study to determine the surgical management of phyllodes tumors is performed.
Results: Within the study period (9 years), 24 patients with Malignant phyllodes Tumor of Breast who met the admission criteria were analyzed. Two groups were established: 75% (n = 18) who left “alive” from the hospital and 25% “deceased” (n = 6). An analysis of the mortality adjusted to the surgical procedure was performed, where it can be observed that the radical mastectomy showed a survival of 82%, while the simple mastectomy and the lumpectomy, procedures chosen as the first option for the treatment of the malignant phyllodes tumor, presented a Survival less than 40%.
Conclusions: The phyllodes malignant breast tumor has a low incidence among malignant breast tumors. It seems that radical mastectomy of the breast is the best option for patients with this type of cancer, and adjuvance does not improve patient survival.